product and process understanding<\/strong>: understanding what happens during freezing, primary drying and secondary drying; assessing the interaction between formulation and cycle; defining the critical quality attributes to be preserved; and building a robust process from the earliest stages of development.<\/p>\nThis approach is decisive for biological medicines and high-value products. In these cases, the margin for error is reduced. Stability of the active ingredient, preservation of biological activity, protection of molecular structure, reconstitution, uniformity and final product quality cannot depend on empirical cycle management.<\/p>\n
Lyophilization therefore becomes a meeting point between formulation and manufacturing. The process cannot be properly designed without knowing the product. At the same time, the product cannot be developed without considering, from the outset, the conditions that will ensure its stability, safety and industrial quality.<\/p>\n
Quality starts with understanding<\/h2>\n
One of the most relevant shifts concerns the move beyond a purely operational view. Lyophilization is not a simple sequence of parameters to be set. It is a complex system in which temperature, pressure, heat transfer, sublimation, matrix characteristics, container, chamber loading and formulation properties all contribute to the final outcome.<\/p>\n
For this reason, increasingly advanced models have been developed over the years to describe what happens during the process and to support the construction of more robust cycles. Modelling does not replace experience, but it makes it more readable, transferable and useful for development decisions. It helps interpret data, anticipate critical issues, reduce unnecessary trials, improve scale-up and define the process operating space with greater awareness.<\/p>\n
From this perspective, lyophilization is fully aligned with the modern culture of pharmaceutical quality<\/strong>. Quality is not created by final control, but by understanding the product and the process. Critical attributes must not only be verified: they must be designed and maintained through coherent formulation, technological and analytical choices.<\/p>\nFor fragile or complex products, this approach is essential. A formulation that is adequate in the laboratory may prove difficult to transfer to industrial scale. A non-optimised cycle can compromise time, yield, stability and reproducibility. Insufficient process knowledge can turn a consolidated technology into a manufacturing bottleneck.<\/p>\n
From formulation to smart manufacturing<\/h2>\n
The title of the PDA event points to a precise direction: from formulation science to smart manufacturing. Lyophilization is entering a phase in which formulation development, process technologies and digital tools must advance together<\/strong>.<\/p>\nThe push towards more advanced equipment, enhanced monitoring systems, analytical tools, sensors, software and predictive models does not respond only to a need for automation. It serves to better govern variability and build more predictable processes.<\/p>\n
Selmin recalls the role of technology providers and companies developing smart solutions to support process development and control. This is an important point, because innovation in lyophilization does not arise from a single area of the value chain. It requires the contribution of those who know formulation, those who design equipment, those who develop measurement tools, those who work in quality, those who operate in production and those who bring engineering and digital expertise.<\/p>\n
In this context, smart manufacturing does not mean adding technology to the process superficially. It means using data and predictive tools to make better decisions: understanding product behaviour, defining more efficient cycles, reducing risks, increasing reproducibility and supporting industrial transfer.<\/p>\n
A multidisciplinary competence<\/h2>\n
Another central theme of the interview is the cross-cutting nature of lyophilization. In pharma, it is often associated with injectable medicines and biologics, but its field of application is broader. It can concern finished products, process intermediates and active pharmaceutical ingredients, and may also have a role in health-related fields, from medical devices to cosmetics.<\/p>\n
This breadth makes a multidisciplinary perspective necessary<\/strong>. There is no single lyophilization approach valid for every product and every context. Formulation issues, stability objectives, regulatory constraints, production requirements and technological configurations must be assessed case by case.<\/p>\nThe value of the PDA event also lies here: bringing academia, industry and technology providers into dialogue. The goal is not only to present innovations, but to create a space for exchange in which different experiences can become shared knowledge. Lyophilization is an area where research, development, quality, production and technology must necessarily communicate.<\/p>\n
Giving space to young professionals<\/h2>\n
A distinctive choice of the event is the involvement of young professionals. PDA Italy Chapter wanted to give greater space to students, researchers and young technical profiles, offering them the opportunity to present results, engage with experts and better understand the prospects opening up within the pharmaceutical industry.<\/p>\n
This is not only a training choice. It is also a strategic one. Advanced pharmaceutical manufacturing will need professionals able to move across different disciplines. Solid scientific skills will be required, together with familiarity with data, models, process technologies, quality, regulatory language and interdisciplinary work.<\/p>\n
In the case of lyophilization, knowing a technique is not enough. One must understand the system: product, formulation, process, critical attributes, control tools and industrial implications. This ability to integrate is what makes the difference.<\/p>\n
A community to accelerate innovation<\/h2>\n
Selmin hopes that the PDA event may represent the first step in a broader path dedicated to lyophilization. Not an isolated event, but the start of a community able to share expertise, cases, problems and solutions.<\/p>\n
The need is clear. The more the value of products increases, the greater the need to understand the process in depth. The more biologics and complex therapies spread, the more important it becomes to design robust and reproducible cycles consistent with the product\u2019s critical attributes.<\/p>\n
In this scenario, innovation does not mean replacing experience with technology. It means making experience more shareable, measurable and transferable. Models, data, smart systems and new equipment make sense when they help build stronger processes and safer products.<\/p>\n
Lyophilization, from a technology perceived as mature, thus becomes a privileged observation point on the future of pharmaceutical manufacturing: a future in which quality is built before the batch, through the ability to design product and process as parts of the same industrial framework.<\/p>\n